Literature DB >> 642157

Continuous intravenous deferoxamine infusion. Treatment of secondary hemochromatosis in adults.

K G Blume, E Beutler, R K Chillar, J L Fahey, D Sharkoff, P K Zia.   

Abstract

Adult patients with chronic iron overload were given oral ascorbic acid and continuous intravenous infusions of deferoxamine mesylate. The dosage of deferoxamine mesylate was altered every 48 hours from 1 g/sq m/24 hr to 2 or 4 g/sq m/24 hr. The average iron mobilization was 55.6 mg per day at the 1 g/sq m/24 hr dosage level, 78.6 mg every 24 hours at the 2 g/sq m/24 hr dosage level, and 90.1 mg every 24 hours at the 4 g/sq m/24 hr dosage level. Iron mobilization was undiminished when successive 14-day courses of deferoxamine separated by six-week intervals were administered.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 642157

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  2 in total

1.  Gallium-67 scintigraphy in patients with hemochromatosis treated by deferoxamine.

Authors:  S Nagamachi; H Hoshi; S Jinnouchi; S Ono; K Watanabe
Journal:  Ann Nucl Med       Date:  1988-05       Impact factor: 2.668

2.  Preparation of 67Ga-labelled human IgG and its Fab fragments using desferoxamine as chelating agent.

Authors:  C Motta-Hennessy; S A Eccles; C Dean; G Coghlan
Journal:  Eur J Nucl Med       Date:  1985
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.